Abstract: |
PURPOSE: Metabolic Syndrome (MetS) is more predominant in overweight, obese and minority populations. This study examined the prevalence of MetS in an exclusively African-American (AA) cohort of breast cancer (BC) survivors; an underrepresented group in previous studies demonstrating negative BC outcomes disparities for females with MetS. METHODS: Using a case-control design, overweight/obese AA women with treated Stage I-IIIa BC were matched 1:1 on age, race, sex, and body mass index (BMI) category with non-cancer population controls (n = 444). Three of the following conditions were used to define MetS: HDL cholesterol /=150 mg/dL (1.7 mmol/L), blood glucose >/=100 mg/dL (or on treatment), waist circumference >/=88 cm, or >/=130 mmHg systolic or >/=85 mmHg diastolic blood pressure (or on treatment). Matched-pairs analyses were conducted. RESULTS: For BC cases, most women had self-reported Stage I (n = 76) or Stage II (n = 91) disease and were 6.9 (+/-5.2) years post-diagnosis. MetS was significantly lower in BC survivors vs. their non-cancer population controls (43.2 vs. 51.4 %, respectively; p /=2 risk factors (80.2 vs. 85.6 %, p 0.05) was observed for all cases vs. CONTROLS: CONCLUSIONS: While MetS occurred less frequently in our BC cases vs. non-cancer controls, our estimates are nearly two times those reported in other BC survivors, suggesting important racial/ethnic differences. IMPLICATIONS FOR CANCER SURVIVORS: The prognostic implications of MetS among AA BC survivors remain unknown and warrant further investigation. |